C. Rudin

发表

Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts : an Evidence Review Group Perspective of a NICE Single Technology Appraisal Running heading Azacitidine for Treating AML with more than 30 % Bone Marrow Blasts

M. Hoyle, Chris Cooper, T. Snowsill, 2018 .

Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results

G. Morgan, W. Gregory, M. Drayson, 2012, Haematologica.

Ponatinib for Treating Chronic Myeloid Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Marrissa Martyn-St James, M. Stevenson, J. Byrne, 2018, PharmacoEconomics.

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.

G. Morgan, W. Gregory, M. Drayson, 2012, Blood.

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.

G. Morgan, W. Gregory, M. Drayson, 2011, Blood.

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

G. Morgan, W. Gregory, M. Drayson, 2010, The Lancet.

Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results

G. Morgan, W. Gregory, M. Drayson, 2014, British Journal of Haematology.

Concordant expression of class II and class III CD34 epitopes on haemopoietic cells in leukapheresis and cord blood samples with CD45/CD34 dual staining

J. Garland, C. Rudin, M. Joyner, 1997, British journal of haematology.

A phase II clinical trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic T-cell lymphoma. An NCRI clinical trial. CRUK number C17050/A5320

Paul A. Smith, W. Townsend, Rod Johnson, 2016, Leukemia & lymphoma.

Re-use of the original infusional induction chemotherapy as salvage therapy in myeloma patients relapsing after one autograft

S. Singhal, J. Mehta, B. Sirohi, 2005, Hematology.

Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: the first step towards an ‘operational cure’?

S. Singhal, J. Mehta, B. Sirohi, 2000, Bone Marrow Transplantation.

Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT.

G. Salles, C. Craddock, P. Biron, 2013, Blood.

Failure of the addition of methylprednisolone to intermediate-dose cyclophosphamide and lenograstim for stem cell mobilization to make the timing of PBSC harvesting more predictable

C. Rudin, J. Hall, J. Melhuish, 2007, Bone Marrow Transplantation.

Collection of peripheral blood stem cells in new patients with myeloma receiving minimal or no prior cytoreductive therapy

G. Morgan, B. Sirohi, R. Powles, 2007, Hematology.

Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.

O. Ukoumunne, T. Pavey, M. Hoyle, 2012, Health technology assessment.

Cytochrome c induces caspase-dependent apoptosis in intact hematopoietic cells and overrides apoptosis suppression mediated by bcl-2, growth factor signaling, MAP-kinase-kinase, and malignant change.

J. Garland, C. Rudin, 1998, Blood.

Evaluation of 13q14 status in multiple myeloma by digital single nucleotide polymorphism technology.

S. Ellard, L. Harries, C. Rudin, 2009, The Journal of molecular diagnostics : JMD.

Investigating the Targets of MIR-15a and MIR-16-1 in Patients with Chronic Lymphocytic Leukemia (CLL)

L. Harries, C. Rudin, K. Hanlon, 2009, PloS one.

Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease

S. Singhal, J. Mehta, B. Sirohi, 2003, Bone Marrow Transplantation.

The implication of compromised renal function at presentation in myeloma

S. Singhal, J. Mehta, N. Raje, 2001, Medical oncology.

Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial

G. Morgan, W. Gregory, M. Drayson, 2011, The Lancet. Oncology.

Reassessing autotransplantation for acute myeloid leukaemia in first remission – a matched pair analysis of autologous marrow vs peripheral blood stem cells

S. Singhal, J. Mehta, M. Labopin, 2004, Bone Marrow Transplantation.

Glomerular filtration rate prior to high-dose melphalan 200 mg/m2as a surrogate marker of outcome in patients with myeloma

S. Singhal, J. Mehta, B. Sirohi, 2001, British Journal of Cancer.

Evaluation of 13q14 status in patients with chronic lymphocytic leukemia using single nucleotide polymorphism-based techniques.

S. Ellard, L. Harries, T. Davies, 2009, The Journal of molecular diagnostics : JMD.

An elective single autograft with high-dose melphalan: single-center study of 451 patients

S. Singhal, J. Mehta, B. Sirohi, 2005, Bone Marrow Transplantation.

An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon-alpha2b in patients with multiple myeloma maintained on a steady dose of interferon-alpha2b.

G. Morgan, A. Leary, B. Sirohi, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria

S. Singhal, J. Mehta, B. Sirohi, 2001, Bone Marrow Transplantation.

Does zoledronic acid (ZOL) reduce skeletal-related events (SREs) and improve progression-free survival (PFS) in patients (Pts) with multiple myeloma (MM) with or without bone disease? MRC myeloma IX study results.

G. Cook, J. Byrne, F. Ross, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Are there benefits to long-term bisphosphonate treatment in multiple myeloma (MM)? Insights from temporal analyses of zoledronic acid (ZOL) versus clodronate (CLO) in the MRC Myeloma IX Trial.

G. Cook, J. Byrne, F. Ross, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts: A Single Technology Appraisal

R. Mújica-Mota, M. Hoyle, Chris Cooper, 2016 .

Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal

M. Hoyle, T. Snowsill, J. Varley-Campbell, 2017, PharmacoEconomics.